Adenovirus-encoded hammerhead ribozyme to PDGF A-chain mRNA inhibits neointima formation after arterial injury

Journal of Vascular Research

Volumn 41, Issue 4, 2004, Pages 305-313

  Lin, Zhi Hong ^a   Fukuda, Noboru ^a   Suzuki, Ryo ^a   Takagi, Hiroto ^a   Ikeda, Yukihiro ^a   Saito, Satoshi ^a   Matsumoto, Koichi ^a   Kanmatsuse, Katsuo ^a   Mugishima, Hideo ^b  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenovirus; Balloon injury; Gene therapy; Neointima formation; PDGF A chain; Prostacyclin; Rat; Ribozyme; Thromboxane; Thrombus formation

Indexed keywords

ADENOVIRUS VECTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR A; PROSTACYCLIN SYNTHASE; PROTEIN; RIBOZYME; THROMBOXANE A2 RECEPTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY MEDIA; ARTICLE; BACTERIAL GENE; BALLOON; CAROTID ARTERY; CONTROLLED STUDY; DRUG SPECIFICITY; ESCHERICHIA COLI; GENE EXPRESSION; INHIBITION KINETICS; INTIMA; LACZ GENE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THROMBOGENESIS; THROMBUS;

ADENOVIRIDAE; ANIMALS; BALLOON DILATATION; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID ARTERY INJURIES; EPOPROSTENOL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RNA, CATALYTIC; RNA, MESSENGER; THROMBOSIS; TUNICA INTIMA; WOUNDS, NONPENETRATING;

EID: 5644254355     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078928     Document Type: Article

References (39)

1. Liu MW, Roubin GS, King SB: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-1387.
2. Schwartz RS, Holmes DR Jr, Topol EJ: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
3. Libby P, Tanaka H: The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97-106.
4. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
5. Noiseux N, Boucher CH, Cartier R, Sirois MG: Bolus endovascular PDGFR-β antisense treatment suppressed intimal hyperplasia in a rat carotid injury model. Circulation 2000;102:1330-1336.
6. Tanizawa S, Ueda M, van der Loos CM, van der Wal AC, Becker AE: Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: An immunohistochemical study. Heart 1996;75:549-556.
7. Johnsson A, Heldin CH, Westermark B, Wasteson A: Platelet-derived growth factor: Identification of constituent polypeptide chains. Biochem Biophys Res Commun 1982;104:66-74.
8. Crowley ST, Ray CJ, Nawaz D, Majack RA, Horwitz LD: Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Physiol 1995;269:H1641-H1647.
9. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin CH: Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1985;82:4418-4422.
10. Miyauchi K, Aikawa M, Tani T, Nakahara K, Kawai S, Nagai R, Okada R, Yamaguchi H: Effect of probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: Possible role of PDGF. Cardiovasc Drugs Ther 1998;12:251-260.
11. Mancini MC, Evans JT: Role of platelet-derived growth factor in allograft vasculopathy. Ann Surg 2000;231:682-688.
12. Pomerantz KB, Hajjar DP: Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis 1989;9:413-429.
13. Todaka T, Yokoyama C, Yanamoto H, Hashimoto N, Nagata I, Tsukahara T, Hara S, Hatae T, Morishita R, Aoki M, Ogihara T, Kaneda Y, Tanabe T: Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 1999;30:419-426.
14. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, Fitzgerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-541.
15. Yamagami S, Miyauchi K, Kimura T, Goh Y, Daida H, Yamaguchi H: Effects of the thromboxane A2 receptor antagonist on platelet deposition and intimal hyperplasia after balloon injury. Jpn Heart J 1999;40:791-802.
16. 2 in cardiac ischemia-reperfusion injury: A study using mice lacking their respective receptors. Circulation 2001;104:2210-2215.
17. Zucker T, Grosser T, Morinelli T, Halushka PV, Sachinidis A, Vetter H, Schror K: Potentiation of PDGF-induced growth responses in coronary artery smooth muscle cells by thromboxane. Agents Actions 1995;45(suppl):53-58.
18. Cech TR, Bass BL: Biological catalysis by RNA. Annu Rev Biochem 1986;55:599-629.
19. Symons RH: Small catalytic RNAs. Annu Rev Biochem 1992;61:641-671.
20. Kotani M, Fukuda N, Ando H, Hu W-Y, Kunimoto S, Kanmatsuse K, Saito S: Chimeric DNA-RNA hammerhead ribozyme targeting to PDGF A-chain mRNA specifically inhibited neointimal formation of rat carotid artery after balloon injury. Cardiovasc Res 2003;57:265-276.
21. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990;1:241-256.
22. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL: Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992;89:2581-2594.
23. Lemarchand P, Jones M, Yamada I, Crystal RG: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-1138.
24. Hu W-Y, Fukuda N, Kotani M, Kanmatsuse K: Adenovirus-mediated transfer of ribozyme targeting PDGF A-chain mRNA inhibits growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002;39:858-865.
25. Hu W-Y, Fukuda N, Kishioka H, Nakayama M, Kanmatsuse K: Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat PDGF A-chain mRNA. J Hypertens 2001;19:203-212.
26. Kanegae Y, Miyake S, Sato Y, Lee G, Saito I: Adenovirus vector technology: An efficient method for constructing recombinant adenovirus and on/off switching of gene expression. Acta Paediatr Jpn 1996;38:182-188.
27. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, Watkins SC, Tzeng E: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
28. Mocharla H, Mocharla R, Hodes ME: Coupled reverse transcription- polymerase chain reaction (RT-PCR) as a sensitive and rapid method for isozyme genotyping. Gene 1990;93:271-275.
29. Hoof T, Riordan JR, Tummler B: Quantitation of mRNA by the kinetic polymerase chain reaction assay: A tool for monitoring P-glycoprotein gene expression. Anal Biochem 1991;196:161-169.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall J: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
31. Waller BF, Pinkerton CA, Orr CM, Slack JD, VanTassel JW, Peters T: Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: A necropsy study of 20 patients. J Am Coll Cardiol 1991;176(suppl B):58B-70B.
32. Ohkawa J, Koguma T, Kohda T, Taira K: Ribozymes: From mechanistic studies to applications in vivo. J Biochem (Tokyo) 1995;118:251-258.
33. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990;247:1222-1225.
34. Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M, Scanlon KJ: The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul 1992;32:195-209.
35. Perlman H, Sata M, Krasinski K, Dorai T, Buttyan R, Walsh K: Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc Res 2000;45:570-578.
36. Badimon L, Badimon JJ, Galvez A, Cjesebro JH, Fuster V: Influence of arterial damage and wall shear rate in platelet deposition. Arteriosclerosis 1986;6:312-320.
37. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Mayer B, Maihac A, Weng D, Shah PK, Badimon L: Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implication for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.
38. Moncada S, Vane JR: Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300:1142-1147.
39. Katugampola SD, Davenport AP: Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001;134:1385-1392.